​

Prelude Therapeutics Ownership | Who Owns Prelude Therapeutics?

OverviewForecastRevenueFinancialsChartTranscripts

Prelude Therapeutics Ownership Summary

Prelude Therapeutics is owned by 50.48% institutional investors, 13.76% insiders, and 35.76% retail investors. Orbimed advisors is the largest institutional shareholder, holding 14.18% of PRLD shares. Vanguard Total Stock Mkt Idx Inv is the top mutual fund, with 1.90% of its assets in Prelude Therapeutics shares.

PRLD Ownership Benchmark

TypeName% Inst% Insiders% Retail
StockPrelude Therapeutics50.48%13.76%35.76%
SectorHealthcare Stocks 245.07%12.10%-157.17%
IndustryBiotech Stocks 380.48%11.73%-292.21%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Orbimed advisors10.91M14.18%$37.31M
Baker bros. advisors lp10.12M13.16%$34.62M
Boxer capital2.57M3.39%$9.79M
Kynam capital management, lp1.59M2.07%$5.45M
Vanguard group1.41M1.86%$4.10M
Blackrock1.07M1.41%$4.07M
Two sigma investments, lp923.63K1.20%$3.16M
Sphera funds management558.34K0.73%$1.91M
Acadian asset management511.52K0.66%$1.75M
Millennium management382.74K0.50%$1.31M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Orbimed advisors10.91M0.74%$37.31M
Boxer capital2.57M0.52%$9.79M
Kynam capital management, lp1.59M0.34%$5.45M
Sphera funds management558.34K0.30%$1.91M
Baker bros. advisors lp10.12M0.20%$34.62M
Shay capital100.00K0.01%$144.00K
Bridgeway capital management53.50K0.00%$182.97K
Acadian asset management511.52K0.00%$1.75M
Two sigma investments, lp923.63K0.00%$3.16M
Renaissance275.20K0.00%$941.18K

Top Buyers

HolderShares% AssetsChange
Kynam capital management, lp1.59M0.34%803.68K
Sphera funds management558.34K0.30%435.59K
Vanguard group1.41M0.00%421.13K
Millennium management382.74K0.00%231.74K
Vanguard fiduciary trust157.38K0.00%157.38K

Top Sellers

HolderShares% AssetsChange
Deerfield management company, l.p. (series c)---3.77M
Ecor1 capital---947.05K
Exoduspoint capital management, lp---921.62K
Avidity partners management lp---890.00K
Price t rowe associates inc /md/---755.96K

New Positions

HolderShares% AssetsChangeValue
Vanguard fiduciary trust157.38K0.00%157.38K$538.24K
Citadel advisors124.38K0.00%124.38K$425.37K
Dimensional fund advisors lp35.21K-35.21K$119.69K
Aqr capital management12.49K-12.49K$15.93K
Graham capital management11.34K0.00%11.34K$38.79K

Sold Out

HolderChange
Nelson, van denburg & campbell wealth management group-1.00
Ifp advisors-1.00
Capital performance advisors llp-8.00
True wealth design-13.00
Srs capital advisors-15.00

Institutional Ownership Trends

DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Jun 30, 20268348.21%49,667,03461.40%503.63%6293.75%9-25.00%
Mar 31, 202613-73.47%1,621,555-94.30%20.15%8-66.67%2-86.67%
Dec 31, 202526-42.22%4,054,360-85.07%50.42%12-20.00%9-52.63%
Sep 30, 202544-2.22%27,161,9481.82%352.90%15-11.76%18-14.29%
Jun 30, 202549-14.04%27,188,001-4.17%352.57%19-9.52%23-4.17%

Top Mutual Funds Shareholders

HolderShares% HoldingChange
Vanguard Total Stock Mkt Idx Inv1.51M1.90%577.82K
Vanguard Morn Total Stk Mkt Idx Investor1.51M1.90%577.82K
Vanguard MStar Total Stk Mkt Idx Invest1.51M1.90%-
Vanguard US Total Market Shares ETF720.43K1.31%-
iShares Russell 2000 ETF719.36K0.90%6.14K
T. Rowe Price Health Sciences516.22K0.82%-40.53K
MFS New Discovery I327.70K0.60%-
Vanguard Institutional Extnd Mkt Idx Tr458.36K0.57%-
Biotech Growth Ord346.50K0.43%-
Fidelity Small Cap Index303.52K0.38%2.18K

Recent Insider Transactions

DateNameRoleActivityValue
Apr 21, 2026Bonita David P Buy$7.50M
Apr 21, 2026Bonita David P Buy$5.00M
Apr 21, 2026ORBIMED ADVISORS LLC Buy$5.00M
Apr 21, 2026ORBIMED ADVISORS LLC Buy$7.50M
Apr 21, 2026BAKER BROS. ADVISORS LP Buy$213.77

Insider Transactions Trends

DateBuySell
2026 Q26-
2026 Q1--
2025 Q4--
2025 Q3--
2025 Q2--

PRLD Ownership FAQ

Who Owns Prelude Therapeutics?

Prelude Therapeutics shareholders are primarily institutional investors at 50.48%, followed by 13.76% insiders and 35.76% retail investors. The average institutional ownership in Prelude Therapeutics's industry, Biotech Stocks , is 380.48%, which Prelude Therapeutics falls below.

Who owns the most shares of Prelude Therapeutics?

Prelude Therapeutics’s largest shareholders are Orbimed advisors (10.91M shares, 14.18%), Baker bros. advisors lp (10.12M shares, 13.16%), and Boxer capital (2.57M shares, 3.39%). Together, they hold 30.72% of Prelude Therapeutics’s total shares outstanding.

Does Blackrock own Prelude Therapeutics?

Yes, BlackRock owns 1.41% of Prelude Therapeutics, totaling 1.07M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 4.07M$. In the last quarter, BlackRock decreased its holdings by -28.558K shares, a -2.60% change.

Who is Prelude Therapeutics’s biggest shareholder by percentage of total assets invested?

Orbimed advisors is Prelude Therapeutics’s biggest shareholder by percentage of total assets invested, with 0.74% of its assets in 10.91M Prelude Therapeutics shares, valued at 37.31M$.

Who is the top mutual fund holder of Prelude Therapeutics shares?

Vanguard Total Stock Mkt Idx Inv is the top mutual fund holder of Prelude Therapeutics shares, with 1.90% of its total shares outstanding invested in 1.51M Prelude Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools